We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Charles River to Buy China's WuXi AppTec

By LabMedica International staff writers
Posted on 03 May 2010
U.S. More...
clinical research company Charles River Laboratories International (Wilmington, MA, USA) has agreed to buy rival WuXi AppTec from parent company WuXi PharmaTech (Shanghai, China) for US$1.6 billion, in an effort to expand its presence in China and deepen its expertise in drug-discovery services.

The combined company, which will retain the name Charles River, will offer a comprehensive portfolio of early-stage drug development services and expanded global presence by creating a global clinical research organizations (CRO) that will offer fully integrated drug development services from molecule creation to first-in-human testing. While Charles River is focused on preclinical and early-stage research, WuXi--one of the biggest Chinese CROs--is active in drug chemistry, such as making molecules to synthesize a drug. The combined company will be led by Charles River Chairman, President, and CEO of James Foster, while WuXi PharmaTech Chairman and CEO Ge Li, Ph.D., will become corporate executive vice president; Dr. Li will also be the president of global discovery and China services, a new segment.

"For the first time, our existing and potential clients will be able to obtain support for their early-stage drug development needs from one company with unparalleled scientific depth and breadth in chemistry and biology," said Mr. Foster, "We have tremendous respect for WuXi and it's skilled team, who have built a market-leading company with a significant presence in China, a region many of our clients consider to be the new frontier for drug development."

"This combination represents a true win-win scenario that significantly expands the global reach and growth opportunities for both companies," said Dr. Li. "As a result of this transaction, Charles River will be able to immediately expand its presence in China and avail itself of WuXi's expertise in chemistry services, while simultaneously WuXi will be in a position to accelerate its good laboratory practice (GLP) toxicology capabilities. Together, we will offer our clients unparalleled support to meet their early-stage drug development needs."

Charles River will offer a total of $21.25 per WuXi American Depositary Share (ADS); each WuXi ADS will get $11.25 in cash and $10 of Charles River common stock, the companies said in the joint statement.

Related Links:

Charles River Laboratories International
WuXi PharmaTech



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Portable POCT Blood Gas Analyzer
BD100
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders

Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more

Microbiology

view channel
Image Credit: 123RF

FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample

Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.